Crystalline forms of gsk1278863, preparation method and pharmaceutical use thereof
AssigneeGlaxosmithkline Intellectual Property (No.2) Limited
InventorsMinhua Chen, Yanfeng Zhang, Jinqiu Wang, Xiaoyu Zhang
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof.
Claims18
A composition of crystalline form CS1 of N-[(1,2-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl]-glycine, wherein the X-ray powder diffraction pattern of form CS1 shows characteristic peaks at 2theta values of 6.4°±0.2°, 7.5°±0.2°, and 7.9°±0.2° using CuKα radiation, and wherein the content of other crystalline forms is less than 10% (w/w).
A composition of crystalline form CS9 of N-[(1,2-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl]-glycine, wherein the X-ray powder diffraction pattern of form CS9 shows characteristic peaks at 2theta values of 4.6°±0.2°, 6.6°±0.2°, and 21.1°±0.2° using CuKα radiation, and wherein the content of other crystalline forms is less than 10% (w/w).
Dependencies are inferred from the claim text.